Market Overview

Quantapore Inc. Attracts Industry Veterans to Board of Directors to Help Drive Commercial Launch


Quantapore Inc. announced the appointment of Dr. Alex Dickinson and
Robert Proulx to the Board of Directors. Both Directors bring a wealth
of experience in the development and commercialization of new
technologies and operating high-growth businesses. Alex and Bob join Dr.
Martin Huber and Dr. Sascha Dennstedt, Quantapore's co-founders as well
as Feng Deng of Northern Light Venture Capital on the Board.

Alex Dickinson has over 25 years of experience founding and leading both
startups and new businesses in large companies. He is the Founder and
Executive Chairman of ChromaCode, a molecular diagnostics company and a
member of the board of directors of PRAH Health Sciences (NASDAQ:PRAH),
a leading contract research organization. Previously, he was a Senior
Vice President at Illumina, Inc. where he developed precision medicine
programs for national healthcare systems and led the team that built
Illumina's cloud-based sequencing informatics platform, BaseSpace. Prior
to joining Illumina, Alex was founder and CEO of Helixis, a molecular
diagnostics company that was acquired by Illumina in 2010. Earlier, Alex
was the founder and CEO of Luxtera, now the world's leading provider of
silicon photonics products. He holds a Ph.D. from the University of
Adelaide, Australia, and an MBA from Columbia University in New York.

"I've had the opportunity to look into many novel sequencing
technologies and Quantapore's approach is the first I've seen that can
really shake up the industry. By combining the long-read capability of
nanopores with the accuracy and scalability of optical base detection,
Quantapore's products will achieve an ease of use and scalability that
can't be matched by other technologies. I'm thrilled to be helping the
company with this next stage."

Robert Proulx is a veteran business executive with more than 25 years of
leadership experience for both private and public companies in the life
science and diagnostic device markets. Currently Bob is the Executive
Chairman and CEO of Imagion Biosystems, a medical imaging company which
is dedicated to providing tools to find and eliminate cancer. Previously
Bob was the President of Silicon Biosystems, where he led the commercial
introduction of an image-based CTC liquid biopsy technology which was
acquired by the Menarini Group in 2013. Bob has held executive positions
at Nanogen, Gene Logic, IGEN and Packard Bioscience. He holds an M.A.
and B.A. from The State University of New York at Albany and an
Executive MBA from the Penn State Smeal College of Business.

"Most products in the life science and healthcare space are incremental
improvements over current methods, so it is very exciting to be invited
to join Quantapore where there is a real opportunity to change the
dynamics in one of the industry's key technology segments."

"Quantapore is fortunate and honored to have Alex and Bob serve on our
Board," said Quantapore's CEO Dr. Martin Huber. "Both have amazing track
records taking disruptive technologies to market by executing effective
strategies and securing the capital to do so. I look forward to
benefitting from their guidance as Quantapore accelerates its journey
toward becoming the leader in genomic sequencing"

About Quantapore Incorporated

Quantapore Inc. is a biotechnology company focused on the development
and commercialization of an ultra-low-cost, high-throughput DNA
sequencing platform. Based in Menlo Park, CA, the company was founded in
2009 and is well on its way to the commercialization of its novel
sequencing platform. The combination of low cost, long reads, simple
workflow and fast sample to result turnaround time holds the promise to
make Quantapore Inc. one of the world's leading sequencing system

View Comments and Join the Discussion!